GeneDx Holdings Corp. is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by rare disease data sets. GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in STAMFORD, Conn.
| Revenue (Most Recent Fiscal Year) | $427.54M |
| Net Income (Most Recent Fiscal Year) | $-21.02M |
| PE Ratio (Current Year Earnings Estimate) | 117.48 |
| PE Ratio (Trailing 12 Months) | 62.49 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 6.04 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.36 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 38.44 |
| Pre-Tax Margin (Trailing 12 Months) | -4.94% |
| Net Margin (Trailing 12 Months) | -4.92% |
| Return on Equity (Trailing 12 Months) | 14.73% |
| Return on Assets (Trailing 12 Months) | 8.67% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.46 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.34 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.16 |
| Inventory Turnover (Trailing 12 Months) | 10.54 |
| Book Value per Share (Most Recent Fiscal Quarter) | $10.54 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.14 |
| Earnings per Share (Most Recent Fiscal Year) | $1.40 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.75 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Health Information Services |
| Common Shares Outstanding | 29.29M |
| Free Float | 20.62M |
| Market Capitalization | $2.58B |
| Average Volume (Last 20 Days) | 0.79M |
| Beta (Past 60 Months) | 2.03 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 29.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 61.72% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |